Costs of cytokine release syndrome (CRS) and neurological events (NE) in patients with relapsed/refractory non-hodgkin lymphoma receiving lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 clinical trial: a micro-costing study from the Spanish National Health System (NHS) perspective
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
